TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance

Sci Adv. 2024 Jan 12;10(2):eadj4457. doi: 10.1126/sciadv.adj4457. Epub 2024 Jan 10.

Abstract

Neurodegenerative diseases such as amyotrophic lateral sclerosis and frontotemporal dementia are associated with substantial sleep disruption, which may accelerate cognitive decline and brain degeneration. Here, we define a role for trans-activation response element (TAR) DNA binding protein 43 (TDP-43), a protein associated with human neurodegenerative disease, in regulating sleep using Drosophila. Expression of TDP-43 severely disrupts sleep, and the sleep deficit is rescued by Atx2 knockdown. Brain RNA sequencing revealed that Atx2 RNA interference regulates transcripts enriched for small-molecule metabolic signaling in TDP-43 brains. Focusing on these Atx2-regulated genes, we identified suppressors of the TDP-43 sleep phenotype enriched for metabolism pathways. Knockdown of Atx2 or treatment with rapamycin attenuated the sleep phenotype and mitigated the disruption of small-molecule glycogen metabolism caused by TDP-43. Our findings provide a connection between toxicity of TDP-43 and sleep disturbances and highlight key aspects of metabolism that interplay with TDP-43 toxicity upon Atx2 rescue.

MeSH terms

  • Amyotrophic Lateral Sclerosis*
  • Animals
  • Ataxin-2
  • DNA-Binding Proteins / genetics
  • Drosophila
  • Humans
  • Neurodegenerative Diseases*

Substances

  • Ataxin-2
  • DNA-Binding Proteins
  • ATX2 protein, Drosophila
  • TBPH protein, Drosophila